ClinicalTrials.gg
Status unknownNCT03491449TICAUpdated Apr 9, 2018

Intensive Treatment of Blood Pressure in Acute Ischemic Stroke. Study TICA 2

An interventional study of Group A and Group B in Brain Ischemia, sponsored by Manuel Rodríguez. Status unknown at 3 sites in Spain. Open to participants aged 18 Years to 85 Years. Per ClinicalTrials.gov, last updated 2018-04-09.

Sponsored by Manuel Rodríguez · Not applicable, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Apr 2018), so the status shown — last known as Recruiting — may be out of date.

From the registry’s dates

  • Registered 1 year after the study started (first participant enrolled Feb 2017, registered Mar 2018).
Phase
Not applicable
Study type
Interventional
Enrollment
90
Allocation
Randomized
Ages
18 Years to 85 Years
Sex
All
01

Study summary

Demonstrate that maintenance of systolic blood pressure between 140 and 160 mm Hg during the acute phase of ischemic stroke is more effective than management according to the International Guideline (treat when systolic blood pressure exceeds 185 mm Hg)

Read the detailed description

Control of blood pressure figures remains one of the most important risk factors in primary and secondary prevention in patients with stroke. The current strategy for the hypertensive treatment of patients during the acute phase of ischemic stroke within the first 72 hours remains a highly debated and unclear issue, with no consensus on the range or appropriate blood pressure ranges to be handled (13).

Team study working hypothesis focuses on the study of blood pressure (for 72 hours), through its intensive control (recording and adjustment every four hours), in the acute phase of ischemic stroke. Specifically, it is based on the monitoring and maintenance of systolic blood pressure between 140 and 160 mm Hg in patients with acute ischemic stroke; And this can lead to a better functional prognosis, measured at 90 days, compared with the functional prognosis of patients treated according to the recommendations of the current Clinical Guidelines, which propose to act on systolic blood pressure only when it exceeds 185 mm Hg (13,22).

Although the intense decrease in blood pressure during the acute phase of stroke has the potential risk of decreasing cerebral perfusion in the area of ischemic penumbra, in recent observational studies (19), a worse functional prognosis has not been found in those patients With systolic blood pressure above 140 mm Hg.

There is no previous evidence from other intervention studies related to blood pressure control and a benefit to patients with acute ischemic stroke. Comparison using a randomized clinical trial of a group of patients with blood pressure control following current guidelines with a group of patients with systolic blood pressure between 140 and 160 mm Hg may allow a simple, rapidly applicable therapeutic alternative to Clinical practice, low cost and extrapolable to a wider population, such as patients with stroke of any etiology.

02

Conditions studied

  • Brain Ischemia

Browse trials for

Keywords

  • Brain ischemia
  • Cerebral ischemia
03

In context

Brain Ischemia

217 studies on the registry are indexed under Brain Ischemia; 42 are open to participants now.

This study's planned enrollment of 90 is above the median of 73 across 140 interventional studies indexed under Brain Ischemia.

Browse Brain Ischemia studies →

Lead sponsor

This is the only study on the registry with Manuel Rodríguez as lead sponsor.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 85 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Men or women aged 18 years and up to and 85 years (both included).
  • Clinical and neuroimaging diagnosis (CT or MRI) of ischemic stroke.
  • Possibility of initiating antihypertensive treatment within 12 hours after the onset of symptoms (in the case of stroke, the start time is considered the time in that the patient has been seen asymptomatic for the last time).
  • Participant with systolic blood pressure greater than or equal to 140 mm Hg and less than or equal to 220 mm Hg at the time of inclusion.
  • Participant or legal representative able to understand the study requirements and sign .

Exclusion criteria

Exclusion Criteria:

  • Uncontrollable hypertension (SBP greater than 220 mm Hg) or any condition requiring urgent antihypertensive treatment.
  • Have suffered a stroke in the previous 90 days in the same territory as the current stroke.
  • Had a myocardial infarction in the previous 90 days.
  • Suspected aortic dissection or hypertensive encephalopathy.
  • Presence of intracerebral or subarachnoid hemorrhage in basal neuroimaging (Computed tomography or magnetic resonance imaging).
  • Recanalization is possible or intraarterial recanalization techniques have been performed due to the current stroke.
  • Known critical carotid occlusion or stenosis.
  • To be a candidate for carotid revascularization in the next three months.
  • Previous alterations that, in the opinion of the investigator, may interfere in the interpretation of the neurological scales.
  • Coma or low level of consciousness (defined as a score ≥ 2 in section 1.a of NIHSS), dementia or mental disability that, in the opinion of the investigator, patient is unable to participate in the study.
  • Convulsive seizures at any time from the onset of symptoms to the initial evaluation.
  • Neurological or non-neurological comorbidities that, in the opinion of the investigator, may lead, regardless of the current stroke, to a deterioration in the patient's neurologic status during the study period, or may hinder the evaluation of the neurological state caused only by stroke (i.e., metabolic encephalopathies, hemiplegic migraine, multiple sclerosis, central nervous system tumor, epilepsy, monocular blindness).
  • Patient is likely to undergo a procedure involving extracorporeal circulation during the study period.
  • Any condition that, in the opinion of the investigator, may compromise the patient's ability to complete the study (i.e., concomitant diseases that may threaten the patient's life, such as neoplasms or terminal failure of an organ).
  • Patient's previous disability, determined by a score in modified Rankin scale > 1.
  • Women of childbearing age with positive pregnancy test or breastfeeding at the time of inclusion.
  • Women of (menopause less than 2 years old or not surgically sterilized) who are not going to take effective and adequate measures to avoid conception during the study period. Control measures include hormonal , barrier methods such as diaphragm or intrauterine devices and / or spermicidal preservatives.
  • Current dependence on substances of abuse such as alcohol, sympathomimetic amines, cannabis, cocaine, hallucinogens, opioids, phencyciclin, sedatives or hypnotics.
  • is less than the expected duration of the clinical trial or any situation that, at the discretion of the investigator, may make participation in the clinical trial dangerous (eg drug use, alcohol addiction, etc.).
  • Have received a drug or product under or participate in a clinical trial within 30 days prior to the date of inclusion in the study.
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorised to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Life expectancy

The study doctor’s estimate of how long someone is likely to live. Criteria use it so that people can stay in the study long enough for it to answer its question.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
90 participants (estimated)

Study arms

  • Experimental
    Group A: pressure ≥140 and ≤160mmHg

    Intensive management of blood pressure, maintaining a systolic blood pressure ≥ 140 and ≤ 160 mm Hg for 72 hours.

    Procedure: Group A

  • Active comparator
    Group B: Keep systolic pressure <185mmHg

    Intensive management of blood pressure, maintaining systolic blood pressure \<185 mm Hg for 72 hours.

    Procedure: Group B

Interventions

  • ProcedureGroup A

    Maintaining a systolic blood pressure ≥ 140 and ≤ 160mm Hg for 72 hours.

  • ProcedureGroup B

    Maintaining a systolic blood pressure \<185mm Hg for 72 hours.

06

What researchers measure

Primary outcomes

  1. Study of functional prognosis in patients with acute ischemic stroke using modified Rankin

    Study of functional prognosis in patients with acute ischemic stroke using modified Rankin scale measured at 90 ± 15 days will compared between the two branches.Rankin Scale: It is a scale that evaluates the patient's functional situation. The full name is "modified Rankin Scale", and the abbreviated name is "mRS". The range of the scale is from 0 to 6, where 0 is the best score (the patient is asymptomatic) and 6 is the worst score (mortality). Up to 2 the patient is considered independent, and from 3 the patient needs help for the activities of daily life.

    Time frame: 90 days

Secondary outcomes

  1. Early Neurological Impairment (ENI)

    Increased at 4 or more points on the NIHSS scale in any determination during the first 72 hours compared to baseline score. NIHSS Scale: It is a scale that evaluates the neurological situation of the patient. The full name is "National Institute of Health Stroke Scale." The lowest score is 0, and the upper limit is 40. The lower score, the patient has fewer symptoms, and the higher score, the patient is more serious. It is considered that up to 8 points the patient has a mild stroke, between 8-15 a moderate stroke and more than 16 points a severe stroke.

    Time frame: 72 hours

  2. Volume of the infarct in neuroimaging

    Volume of the infarct in neuroimaging (CT or MRI) performed between the 4th and 7th day after the stroke. The volume in mL, using the formula a x b x c x 0.5, where "a" and "b" are the largest diameters perpendicular in centimeters and "c" the number of 1 cm cuts in which the infarct is seen.

    Time frame: 4th day

  3. Mortality

    Any patient who dies from inclusion (signature of informed consent) until the final study visit (90 ± 15 days).

    Time frame: 90 days

  4. Measuring the adverse events

    Measuring the adverse events occurring throughout the study.

    Time frame: 90 days

  5. Volume of the infarct using NIHSS

    Increased at 4 or more points on the NIHSS scale in any determination during the first 72 hours compared to baseline score. NIHSS Scale: It is a scale that evaluates the neurological situation of the patient. The full name is "National Institute of Health Stroke Scale." The lowest score is 0, and the upper limit is 40. The lower score, the patient has fewer symptoms, and the higher score, the patient is more serious. It is considered that up to 8 points the patient has a mild stroke, between 8-15 a moderate stroke and more than 16 points a severe stroke.

    Time frame: 7th day

07

Study locations

3 of 3 sites recruiting
  • Hospital Clínico Universitario de Santiago
    Santiago de Compostela, A Coruña 15706, Spain
    Recruiting
  • Hospital Universitario Álvaro Cunqueiro
    Vigo, Pontevedra 36312, Spain
    Recruiting
  • Hospital Universitario A Coruña
    A Coruña, 15006, Spain
    Recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Feb 2017 (actual). Primary completion is estimated for Feb 2019, 24 months after the start.

Of 43 interventional studies with no phase under Brain Ischemia, half reached primary completion within 28 months of starting (the median), counting those still running; a quarter within 16 and three quarters within 53. This study's planned 24 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 6, 2018
First posted
Apr 9, 2018
StartActual
Feb 13, 2017
Primary completionEst.
Feb 13, 2019
CompletionEst.
Feb 13, 2020
Last update
Apr 9, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 9, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03491449
Lead sponsor
Manuel Rodríguez
Responsible party
Manuel Rodríguez (Principal Investigator, Hospital Clinico Universitario de Santiago) — Sponsor-investigator
First posted
Apr 9, 2018
Start date
Feb 13, 2017
Primary completion
Feb 13, 2019 (estimated)
Completion
Feb 13, 2020 (estimated)
Last update
Apr 9, 2018

Study contacts

Manuel Rodríguez, MD
Contact
manyanez@yahoo.es
+34981950000
Manuel Rodríguez, MD
principal investigator · Hospital Universitario de Santiago

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion